Intra-Cellular Therapies Inc. (NASDAQ:ITCI) saw unusually-strong trading volume on Monday . Approximately 1,343,504 shares traded hands during mid-day trading, an increase of 172% from the previous session’s volume of 494,262 shares.The stock last traded at $42.98 and had previously closed at $42.72.

Several research analysts have issued reports on ITCI shares. Leerink Swann reissued an “outperform” rating on shares of Intra-Cellular Therapies in a research report on Saturday, April 16th. Cowen and Company reissued a “buy” rating on shares of Intra-Cellular Therapies in a research report on Thursday, April 28th. Zacks Investment Research cut Intra-Cellular Therapies from a “hold” rating to a “sell” rating in a research report on Friday, April 29th. Finally, Piper Jaffray Cos. started coverage on Intra-Cellular Therapies in a research report on Wednesday, June 1st. They issued an “overweight” rating and a $57.00 target price on the stock. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. Intra-Cellular Therapies presently has an average rating of “Buy” and a consensus target price of $70.78.

The company has a 50-day moving average price of $39.61 and a 200-day moving average price of $34.72. The firm’s market cap is $1.86 billion.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Thursday, August 4th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.79) by $0.08. The business had revenue of $0.23 million for the quarter, compared to analyst estimates of $0.02 million. The company’s quarterly revenue was up 283.3% on a year-over-year basis. During the same period in the prior year, the company earned ($0.61) earnings per share. Equities analysts anticipate that Intra-Cellular Therapies Inc. will post ($3.17) earnings per share for the current year.

A number of hedge funds and institutional investors have made changes to their positions in ITCI. Jennison Associates LLC raised its position in shares of Intra-Cellular Therapies by 212.9% in the fourth quarter. Jennison Associates LLC now owns 1,257,846 shares of the biopharmaceutical company’s stock valued at $67,660,000 after buying an additional 855,846 shares in the last quarter. California Public Employees Retirement System raised its position in shares of Intra-Cellular Therapies by 505.4% in the fourth quarter. California Public Employees Retirement System now owns 78,700 shares of the biopharmaceutical company’s stock valued at $4,233,000 after buying an additional 65,700 shares in the last quarter. BlackRock Advisors LLC raised its position in shares of Intra-Cellular Therapies by 1.7% in the fourth quarter. BlackRock Advisors LLC now owns 1,199,043 shares of the biopharmaceutical company’s stock valued at $64,497,000 after buying an additional 19,938 shares in the last quarter. Rhumbline Advisers raised its position in shares of Intra-Cellular Therapies by 33.1% in the fourth quarter. Rhumbline Advisers now owns 25,503 shares of the biopharmaceutical company’s stock valued at $1,372,000 after buying an additional 6,345 shares in the last quarter. Finally, New York State Common Retirement Fund raised its position in shares of Intra-Cellular Therapies by 27.9% in the fourth quarter. New York State Common Retirement Fund now owns 26,600 shares of the biopharmaceutical company’s stock valued at $1,431,000 after buying an additional 5,800 shares in the last quarter.

Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.